Appln. No.: 10/578,660 Group Art Unit No.: 1625

REMARKS

The claims are 88-116, with claims 88, 89, 92 and 102 being independent. Claims 1-87 have been canceled without prejudice or disclaimer. Support for claims 88-116 may be found throughout the specification, and particularly in previously pending claims 1-87.

Applicants wish to direct the Examiner's attention to Examples 22 and 23 of US5,734,056 (which is already of record in this case) for other methods of recrystallization of topotecan hydrochloride.

Applicants respectfully submit that the subject application is in condition for allowance.

If the Examiner has any remaining objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned attorney using the contact information provided below.

Authorization is hereby granted to charge any fees (e.g., under 37 C.F.R. §1.17) required to obtain entry and consideration of this paper to Deposit Account 19-2570.

Respectfully submitted,

Kathryn L. Sieburth Attorney for Applicants Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\KLS\Cases\PU60518\USNATL\RCE2 Amendment.doc